Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 20/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | FPR1 | P21462 | 1/20 | 0.43 |
| ▸ | TACR3 | P29371 | 1/20 | 0.43 |
| ▸ | GPR183 | P32249 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6355420 | 1.00 | TACR1 (0.44) | TACR1NR3C1CYP3A4FPR1TACR3 | |
| SCHEMBL7553900 | 1.00 | TACR1 (0.44) | TACR1NR3C1CYP3A4FPR1TACR3 | |
| SCHEMBL4689468 | 0.92 | TACR1 (0.43) | TACR1NR3C1CYP3A4FPR1TACR3 | |
| SCHEMBL7547903 | 0.90 | TACR1 (0.45) | TACR1NR3C1CYP3A4FPR1TACR3 | |
| SCHEMBL7682591 | 0.90 | TACR1 (0.45) | TACR1NR3C1CYP3A4FPR1TACR3 | |
| SCHEMBL7550074 | 0.90 | TACR1 (0.45) | TACR1NR3C1CYP3A4FPR1TACR3 | |
| SCHEMBL6616379 | 0.90 | TACR1 (0.55) | TACR1NR3C1CYP3A4FPR1TACR3 | |
| SCHEMBL4689319 | 0.90 | TACR1 (0.55) | TACR1NR3C1CYP3A4FPR1TACR3 | |
| SCHEMBL6353098 | 0.90 | TACR1 (0.55) | TACR1NR3C1CYP3A4FPR1TACR3 | |
| SCHEMBL5409410 | 0.90 | TACR1 (0.55) | TACR1NR3C1CYP3A4FPR1TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020035132-A1 | Tetrahydropyran derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2002-03-21 | — | — | US | claimed |
| US-6489343-B2 | PSYCHOLOGICAL DISORDERS; NERVOUS SYSTEM DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 2002-12-03 | — | — | US | disclosed |
| US-20020035132-A1 | Tetrahydropyran derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2002-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035132-A1 | Tetrahydropyran derivatives and their use as therapeutic agents | GRM1, GRM2, OPRM1 | TACR1 1103/4885NR3C1 154/4885CYP3A4 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.